Gravitate-Health

Gravitate–Health: Empowering and equipping Europeans with health information for active personal health management and adherence to treatment
Ongoing | IMI2 |
Gravitate-Health logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 18
Grant agreement number
945334

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
9 280 000
EFPIA in kind
9 150 000
Associated Partners
25 000
Other
106 750
Total Cost
18 561 750

Summary

Vast amounts of information on medicines is available, especially online, but it is very hard to know what is reliable or even relevant for a specific patient. And, while each medicine comes with a detailed information leaflet, patients often find these difficult to read and understand.

This is an issue because when patients lack important information about their treatments, they may not take them correctly and this can result in further health problems. The OECD (Organisation for Economic Cooperation and Development) estimates that poor medication adherence may contribute to around 200 000 premature deaths in Europe every year.

The aim of Gravitate-Health is to develop a digital health information tool called the Gravitate Lens (G-Lens). As the name suggests, the G-Lens will focus (but not conceal or filter) approved information on medicines and guide patients to understandable, trustworthy, up-to-date information that meets the patient’s needs and fits with their health context and literacy levels. The functionality of the G-Lens will be supported by an open source digital platform.

More broadly, the project hopes to demonstrate that by making information on medicines more accessible and understandable, patients will be more likely to take their medicines correctly, resulting in better health outcomes and quality of life.

All stakeholders relevant to digital health information are involved in the project, including patient representatives, regulators, ministries, digital technology experts and more.

In addition to the open source platform underlying the G-Lens, the project will produce a white paper with recommendations on realistic strategies on the future use of digital services like electronic product information can be used to further minimise the risks associated with incorrect adherence to advice on medicines.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Grunenthal GMBH, Aachen, Germany
  • Mdsol Europe LTD, London, United Kingdom
  • Mylan Ire Healthcare Limited, Dublin, Ireland
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • UCB Biopharma SRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
  • Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands
  • Akershus Universitetssykehus Hf, Lorenskog, Norway
  • Beth Israel Deaconess Medical Center, Inc Non Profit Corporation, Boston Ma, United States
  • Echalliance Company Limited By Guarantee, Dublin, Ireland
  • Hl7 International Fondation, Brussels, Belgium
  • Karolinska Institutet, Stockholm, Sweden
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Servicio Madrileno De Salud, Madrid, Spain
  • Spms - Servicos Partilhados Do Ministerio Da Saude Epe, Lisboa, Portugal
  • Statens Legemiddelverk, Oslo, Norway
  • The European Institute For Innovation Through Health Data, Gent, Belgium
  • Trinity College Dublin, Dublin, Ireland
  • Universidad Politecnica De Madrid, Madrid, Spain
  • Universita Cattolica Del Sacro Cuore, Milan, Italy
  • Universitetet I Oslo, Oslo, Norway
  • Universitetssykehuset Nord-Norge Hf, Tromso, Norway
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Datawizard SRL, Roma, Italy
  • Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany
  • Frisq Holding AB, Stockholm, Sweden
  • Guardtime Ou, Tallinn, Estonia
  • Himss Europe GMBH, Berlin, Germany
  • Mindview Symvouloi Epixeiriseon Kaierevnas Etaireia Periorismenis Efthynis, Athens, Greece
  • Norsk E Helse As, Oslo, Norway
  • Open Evidence, Barcelona, Spain
  • The Synergist, Bruxelles, Belgium
  • Trifork Public As, Aarhus C, Denmark
Patient organisations
  • Forum Des Patients Europeens, 1040, Belgium
Associated partners
  • Datapharm Limited, Leatherhead, United Kingdom
Third parties
  • Synergist Services, Bruxelles, Belgium
Project coordinator
Anne Moen
Universitetet I Oslo